AlphaQuest LLC Has $117,000 Stake in Nurix Therapeutics, Inc. $NRIX

AlphaQuest LLC lessened its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 72.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,636 shares of the company’s stock after selling 33,629 shares during the quarter. AlphaQuest LLC’s holdings in Nurix Therapeutics were worth $117,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its stake in shares of Nurix Therapeutics by 118.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock valued at $73,000 after buying an additional 3,475 shares during the period. Velan Capital Investment Management LP bought a new stake in Nurix Therapeutics in the second quarter valued at approximately $114,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Nurix Therapeutics during the 2nd quarter valued at approximately $141,000. Sei Investments Co. acquired a new stake in Nurix Therapeutics during the 2nd quarter valued at approximately $158,000. Finally, KLP Kapitalforvaltning AS raised its holdings in Nurix Therapeutics by 38.7% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 15,400 shares of the company’s stock worth $175,000 after purchasing an additional 4,300 shares during the last quarter.

Insider Activity

In other Nurix Therapeutics news, insider Gwenn Hansen sold 4,895 shares of the firm’s stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $16.60, for a total value of $81,257.00. Following the completion of the transaction, the insider owned 83,672 shares in the company, valued at $1,388,955.20. This trade represents a 5.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Houte Hans Van sold 3,661 shares of the stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $16.60, for a total transaction of $60,772.60. Following the completion of the sale, the chief financial officer owned 45,427 shares in the company, valued at $754,088.20. This represents a 7.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.40% of the stock is owned by company insiders.

Nurix Therapeutics Stock Down 0.8%

NRIX stock opened at $15.60 on Friday. The firm has a market cap of $1.60 billion, a PE ratio of -5.13 and a beta of 1.96. The business has a 50 day moving average of $18.32 and a 200-day moving average of $13.69. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $22.50.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Wednesday, January 28th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.02. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 57.51%. The company had revenue of $13.58 million during the quarter, compared to analyst estimates of $13.41 million. On average, research analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NRIX. Royal Bank Of Canada boosted their price objective on Nurix Therapeutics from $28.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, January 29th. Wells Fargo & Company dropped their price target on Nurix Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Thursday, January 29th. Truist Financial initiated coverage on shares of Nurix Therapeutics in a research report on Monday, November 24th. They set a “buy” rating and a $30.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Thursday, January 22nd. Finally, BTIG Research restated a “buy” rating and issued a $30.00 price target on shares of Nurix Therapeutics in a report on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.